May 06, 2026
A New Jersey federal judge won't ask the Supreme Court of Minnesota to weigh in on whether an insurer can pursue claims using a state law typically reserved for the attorney general in litigation alleging drugmaker Celgene used charitable donations to manipulate the price of cancer drugs.
June 06, 2024
A New Jersey federal judge granted drugmakers Celgene and Bristol-Myers Squibb an out from consolidated antitrust litigation accusing them of delaying generic competition to their blockbuster cancer treatments, saying the conduct alleged by a group of insurer plaintiffs fails to amount to anti-competitive conduct.
May 22, 2024
Celgene and parent Bristol-Myers Squibb pointed a New Jersey federal judge to the dismissal, recently upheld by the Second Circuit, of an antitrust suit over delayed generic competition to AbbVie's hypertension treatment Bystolic to argue the same logic applies to their bid to duck antitrust claims over cancer therapies.
December 05, 2023
Celgene and parent Bristol-Myers Squibb expressed frustration Tuesday about the timing of a Blue Cross unit's decision to bow out as a plaintiff in New Jersey federal court antitrust litigation accusing the drugmakers of delaying generic competition to blockbuster cancer treatments, raising concerns the insurer might shirk its discovery obligations.
April 21, 2023
A New Jersey federal magistrate judge refused Friday to pump the brakes on consolidated antitrust lawsuits accusing Celgene and parent Bristol-Myers Squibb of conspiring with generic drugmakers Teva and Natco to delay generic competition to blockbuster cancer treatments, preferring to get a move on with the years-old litigation.